COVID-19 vaccination in Denmark

Last updated

Denmark started vaccinating against COVID-19 on 27 December 2020. [1] Vaccination in Denmark is free of cost and voluntary. [1] It is available to all residents of Denmark and those from abroad staying for more than 30 days in Denmark. [1] Denmark has one of the highest levels of COVID-19 vaccination in the European Union as of the end of September 2021. [2]

Contents

Vaccines on order

There are several COVID-19 vaccines at various stages of development around the world.

VaccineApprovalDeployment
Pfizer–BioNTech Green check.svg 21 December 2020Green check.svg 27 December 2020
Moderna Green check.svg 6 January 2021Green check.svg 12 January 2021
Oxford-AstraZeneca Green check.svg 29 January 2021Green check.svg 7 February 2021
Janssen J&J Green check.svg 11 March 2021Green check.svg April 2021
CureVac PendingPending
Novavax PendingPending
Valneva PendingPending
Sanofi–GSK PendingPending

Vaccine calendar

The priority order for vaccination and scheduled time period for administering vaccine for each priority group is determined using a Vaccine Calendar in Denmark. [3] The 10 target groups in descending order of priority are as follows:

  1. Residents in nursing homes.
  2. People over 65 years who receive both personal care and practical assistance.
  3. People aged over 85 years.
  4. Healthcare professionals, elderly care professionals and others who are identified to be at risk for infection or are performing a critical function in the society.
  5. Persons with pre-existing conditions who have significantly higher risk for severe illness from COVID-19.
  6. Relatives of individuals or caregivers who are at increased risk of severe illness from COVID-19.
  7. Age group of 80-84.
  8. Age group of 75-79.
  9. Age group of 65-74.
  10. Other age groups.

As of June 2021, children younger than 12 years and pregnant women are not offered vaccination in Denmark. [4]

Available vaccines

Denmark uses Pfizer/BioNTech and Moderna vaccines. Denmark was the first country in Europe to stop using Oxford-AstraZeneca as well as Janssen J&J vaccines by citing blood clots as side effects, despite the approval of these vaccines by the European Medicines Agency. [5] [6] As of May 2021, it became possible for Danish citizens to opt-in to receive any of these vaccines, although these vaccines were not included in the Danish vaccination program. [7]

Related Research Articles

The Joint Committee on Vaccination and Immunisation (JCVI) is an independent expert advisory committee that advises United Kingdom health departments on immunisation, making recommendations concerning vaccination schedules and vaccine safety. It has a statutory role in England and Wales, and health departments in Scotland and Northern Ireland may choose to accept its advice.

Oxford–AstraZeneca COVID-19 vaccine Viral vector vaccine for prevention of COVID-19 by Oxford University and AstraZeneca

The Oxford–AstraZeneca COVID-19 vaccine, codenamed AZD1222, and sold under the brand names Covishield and Vaxzevria among others, is a viral vector vaccine for prevention of COVID-19. Developed in the United Kingdom by the Oxford University and British-Swedish company AstraZeneca, it is given by intramuscular injection, using as a vector the modified chimpanzee adenovirus ChAdOx1. Studies carried out in 2020 showed that the efficacy of the vaccine is 76.0% at preventing symptomatic COVID-19 beginning at 22 days following the first dose and 81.3% after the second dose. A study in Scotland found that, for symptomatic COVID-19 infection after the second dose, the vaccine is 81% effective against the Alpha variant, and 61% against the Delta variant.

COVID-19 vaccination in the United Kingdom Immunisation against COVID-19

The COVID-19 vaccination programme in the United Kingdom is an ongoing mass immunisation campaign for coronavirus disease 2019 (COVID-19) during the COVID-19 pandemic in the United Kingdom. The UK's vaccination rollout was the world's first mass immunisation programme for the disease when it began on 8 December 2020 after Margaret Keenan received her first dose of two. As of 29 September 2021, 48,829,118 first doses and 44,867,373 second doses of a vaccine had been administered across the UK.

The COVID-19 vaccination program in the Philippines is an ongoing mass immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

COVID-19 vaccination in Australia Ongoing COVID-19 vaccine program in Australia

The general COVID-19 vaccination in Australia programme began on 22 February 2021 in response to the COVID-19 pandemic, and will continue with the goal of vaccinating all willing Australians before 2022. Front-line workers and aged care staff and residents will be the first Australians to be inoculated, before a gradual phased release to less-vulnerable and lower-risk population groups throughout 2021. The Therapeutic Goods Administration (TGA) approved four vaccines for Australian use in 2021: the Pfizer–BioNTech vaccine on 25 January, the Oxford–AstraZeneca vaccine on 16 February, Janssen vaccine on 25 June and the Moderna vaccine on 9 August. Although approved for use, the Janssen vaccine is not included in the Australian vaccination program.

European Commission–AstraZeneca COVID-19 vaccine dispute Dispute between the European Union and AstraZeneca

A dispute broke out in January 2021 between the European Commission and the pharmaceutical company AstraZeneca AB about the provision of COVID-19 vaccines during the COVID-19 pandemic, and, in February, spilled out into a dispute over Article 16 of the Northern Ireland Protocol. Vaccination proceeded apace in the UK but more slowly in the EU, and by the end of March 2021, over 30% of the UK population had received at least one dose of vaccine compared to about 8% of the EU population. This was partly due to limited availability of the AstraZeneca vaccine in the EU. The World Health Organization and the European Medicines Agency continued to state that the vaccine was safe and effective. However, a representative of the European Medicines Agency said in June that vaccines based on the mRNA technology should be preferred if available for all age groups, including for the over 60s.

COVID-19 vaccination in France

COVID-19 vaccination in France started on 27 December 2020 after the approval of Pfizer/BioNTech vaccine by the European Union commission.

COVID-19 vaccination in Romania started on 27 December 2020. It was announced that the process would be divided into three phases. Medical personnel would be vaccinated first, followed by the population at risk, and finally by the rest of the population. Vaccination was declared free and non-mandatory. As of May 2021, four types of vaccines were authorized to be used in Romania. This is the largest vaccination campaign in the modern history of Romania.

COVID-19 vaccination in the Republic of Ireland Plan to immunise against COVID-19

COVID-19 vaccination in the Republic of Ireland began on 29 December 2020, in response to the ongoing pandemic in the Republic of Ireland. As of 30 September 2021, 3,771,808 people had received the first dose of a vaccine, 3,446,993 had received their second dose and 235,674 had received a single dose, bringing the total of vaccines administered to 7,218,801.

COVID-19 vaccination in Canada COVID-19 vaccination programme in Canada

The COVID-19 vaccination program in Canada is an ongoing, intergovernmental effort coordinated between the bodies responsible in the Government of Canada to acquire and distribute vaccines to individual provincial and territorial governments who in turn administer authorized COVID-19 vaccines during the COVID-19 pandemic in Canada. Some provinces have asked local municipal governments, hospital systems, family doctors and independently owned pharmacies to aid in part, or in full with vaccination rollout. The vaccination effort in full is the largest such immunization effort in the nation's history; it started in mid-December 2020 and is currently ongoing.

COVID-19 vaccination in Africa Immunisation programme against COVID-19 in Africa

COVID-19 vaccination programs have begun in many countries and territories in Africa. As of 5 July 2021, vaccination campaigns had started in 51 African countries with 36.5 million people receiving at least one dose.

COVID-19 vaccination in Bhutan

Bhutan has promised a free COVID-19 vaccination to all of its citizens, both inside and outside the country. It started mass vaccinations on 27 March 2021.

Embolic and thrombotic events after COVID-19 vaccination Post vaccination adverse effects

Post-vaccination embolic and thrombotic events, also termed vaccine-induced prothrombotic immune thrombocytopenia (VIPIT), vaccine-induced immune thrombotic thrombocytopenia (VITT), or thrombosis with thrombocytopenia syndrome (TTS) are rare types of blood clotting syndromes that were initially observed in a very small number of people who had previously received the Oxford–AstraZeneca COVID-19 vaccine (AZD1222) during the COVID-19 pandemic. It was subsequently also described in the Janssen COVID-19 vaccine leading to suspension of its use until its safety had been reassessed.

The COVID-19 vaccination campaign in Quebec is an ongoing provincial effort to distribute and administer the vaccine against COVID-19.

COVID-19 vaccination in Indonesia

The COVID-19 vaccination in Indonesia is an ongoing mass immunization in response to the COVID-19 pandemic in Indonesia. On 13 January 2021, the program commenced when President Joko Widodo was vaccinated at the presidential palace.

COVID-19 vaccination in Germany

The COVID-19 vaccination campaign in Germany began on 26 December 2020. As of 19 September 2021, 55,869,314 people have received at least one dose, while 52,503,166 people have been fully vaccinated.

COVID-19 vaccination in Brazil

The COVID-19 vaccination campaign in Brazil is an ongoing mass immunization campaign for the COVID-19 pandemic in Brazil. It started in January 17, 2021, when the country had 210 thousand deaths.

COVID-19 vaccination in Iceland is an effort to immunize the adult population of Iceland due to the COVID-19 pandemic. As of July 2021, more than 260,000 individuals have received at least one dose of COVID-19 vaccine, which is over 78% of the country's population. The vaccines approved for use in Iceland are Pfizer, Moderna, AstraZeneca, Janssen. Iceland has also signed a contract with CureVac.

COVID-19 vaccination in Taiwan Plan to immunize against COVID-19

COVID-19 vaccination in Taiwan is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in response to the ongoing pandemic in the country. Following the approval of the Oxford–AstraZeneca COVID-19 vaccine on 18 March 2021, vaccinations commenced on 22 March 2021, and will continue throughout the year with the goal of vaccinating 60% of the population by October 2021.

References

  1. 1 2 3 "Danske Regioner - The Danish COVID-19 vaccination programme". www.regioner.dk (in Danish). Retrieved 4 July 2021.
  2. Kottasová, Ivana (1 October 2021). "They have all the vaccines they need, yet these EU nations are still miles behind their neighbors". CNN. Retrieved 2021-10-01.
  3. "Vaccination calendar". www.sst.dk. Retrieved 4 July 2021.
  4. "Who are offered vaccination?". www.sst.dk. Retrieved 5 July 2021.
  5. "Denmark offers AstraZeneca and J&J COVID-19 vaccines to volunteers". euronews. 20 May 2021. Retrieved 5 July 2021.
  6. "Denmark drops Johnson and Johnson COVID vaccine over side effect fears". euronews. 3 May 2021.
  7. "Tilvalgsordningen for Covid-19 vacciner træder i kraft i denne uge". sum.dk (in Danish). Retrieved 5 July 2021.